SOS1 and chronic myelogenous leukemia, BCR-ABL1 positive: These data demonstrate that SIAIS562055 combined with imatinib enhanced the antitumor activity of the latter, further highlighting the beneficial advantages of PROTAC-based SOS1 degradation in CML therapy.